We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

PLPC:NASDAQPreformed Line Products Company Analysis

Data as of 2026-05-19 - not real-time

$335.43

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

Preformed Line Products is trading around $335, comfortably above its 20‑day SMA of $342.76 but still higher than the 50‑day ($306.72) and 200‑day ($239.43) averages, indicating a lingering bullish bias. Technical momentum is weakening as the MACD line sits below its signal (bearish) and the histogram is negative, while the RSI at 51 suggests the stock is neither overbought nor oversold. Volume has been decreasing, and the 30‑day volatility is high at roughly 72%, underscoring short‑term price instability. Fundamentally, the company posted strong top‑line growth of 18.7% YoY and maintains a healthy cash flow profile, but a trailing PE of 48× dwarfs the industry average of 29×, and a DCF‑derived fair value of $87 signals significant overvaluation. The dividend yield is modest at 0.24% with a low payout ratio of 12%, supporting dividend sustainability. Debt levels are modest relative to equity (debt‑to‑equity ~10.5) and the balance sheet remains solid. The market sentiment is extremely bullish (Fear & Greed Index 88.98), yet the upside potential is limited to about 11% above the current price, while downside risk remains higher. Consequently, the stock sits at a crossroads: bullish trend signals remain, but valuation and technical momentum caution investors.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 5/10

Key Factors

  • Bearish MACD crossover
  • Decreasing volume trend
  • Price near recent support

Medium Term

1–3 years
Neutral
Model confidence: 6/10

Key Factors

  • SMA hierarchy still bullish
  • Strong revenue growth
  • Elevated valuation relative to peers

Long Term

> 3 years
Positive
Model confidence: 7/10

Key Factors

  • Sustained earnings and cash flow generation
  • Low dividend payout supporting future growth
  • Potential price correction aligning with DCF fair value

Key Metrics & Analysis

Financial Health

Revenue Growth18.70%
Profit Margin4.92%
P/E Ratio48.3
ROE7.54%
ROA5.53%
Debt/Equity10.47
P/B Ratio3.5
Op. Cash Flow$73.9M
Free Cash Flow$14.6M
Industry P/E29.5

Technical Analysis

TrendBullish
RSI51.1
Support$306.91
Resistance$371.80
MA 20$342.76
MA 50$306.72
MA 200$239.43
MACDBearish
VolumeDecreasing
Fear & Greed Index88.98

Valuation

Fair Value$87.20
Target Price$372.00
Upside/Downside10.90%
GradeOvervalued
TypeGrowth
Dividend Yield0.24%

Risk Assessment

Beta1.80
Volatility71.98%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.